AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication

WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.

"COPD is a serious, debilitating lung disease affecting 12 million Americans,(1)" said lead investigator Dr. Donald Tashkin of the University of California, Los Angeles (UCLA). "If SYMBICORT receives approval from the FDA to help manage COPD, it could offer the millions of people living with this disease a new treatment option."

The sNDA submission is based on results from two pivotal efficacy and safety trials, SHINE and SUN, with SYMBICORT pressurized metered dose inhaler (pMDI).(2),(3) Of note, both trials showed a safety profile consistent with the established profiles for this product and its mono-components.(2),(3) The most common adverse events found in these trials were bronchitis, oral candidiasis, viral upper respiratory tract infection and nasopharyngitis, also known as the common cold.(2),(3)

"SYMBICORT is a combination maintenance treatment for patients with asthma that works rapidly to help improve lung function by reducing inflammation in the lining of the lung, (4),(8)" said Howard Hutchison, Chief Medical Officer, AstraZeneca. "We are confident in the data from the SHINE and SUN trials that support our submission, and we look forward to discussions with the FDA about this potential expanded indication."

About COPD

More than 12 million people in the United States suffer from COPD, and it is the fourth leading cause of death in the nation.(1) Some estimates also suggest that 12 million more people have COPD but are undiagnosed.(1) COPD is a term referring to two serious lung diseases -- emphysema and chronic bronchitis -- that cause a person's airways to become inflamed over time, making it difficult to breathe normally.(1) Common symptoms include shortness of breath, chronic cough, wheezing and excess mucus.(1) For patients with moderate to very severe COPD, to reduce exacerbations and improve lung function and health status, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the use of combination treatments with an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), in addition to other treatment options.(6) COPD is a progressive disease, which means people with COPD can expect lung function to worsen over time.(6) When symptoms are severe, it can be difficult for a person to perform simple, daily tasks.(1) As the disease progresses, people with COPD may eventually require supplemental oxygen and may have to rely on mechanical ventilatory assistance.(7)

About SYMBICORT

SYMBICORT is a combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older.(4) Administered twice daily, SYMBICORT is a combination of two proven asthma medications -- budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA).(4) SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.(4)

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in greater than or equal to 5 percent of patients, regardless of relationship to treatment, include nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort.

Please see full Prescribing Information and visit www.MySYMBICORT.com

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

SOURCE AstraZeneca

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.